Backcasting-type approach to support the development of regenerative medicine products

To overcome the River of Demons, the Valley of Death, and Darwin's Sea

Support for the development of regenerative medical products through a backcasting approach

News Notice

2025.05.23
Our website is now open!

Vision Vision of Regenerative Medicine Platform

Aiming for clinical development and social implementation through business support from an industry-academia collaboration team with an exit perspective

We aim to overcome the difficulties of basic and applied research, which are known as the River of Demons, the Valley of Death, and Darwin's Sea, and to provide actual products and services to society, and we aim to promote clinical development in Japan and overseas and deliver them to patients.

Mission Mission of the Regenerative Medicine Platform

We aim to provide the following support in order to link technologies and discoveries that are at the stage of basic and applied research to social implementation and clinical development.

Early Stage Clinical Trial Planning -and Preparation: Support for planning regulatory strategies, manufacturing investigational drugs, and designing early-stage clinical trials with an eye to starting clinical trials.

Assessment of business feasibility and preparation of strategy: We support researchers in understanding the commercial potential of their research from an early stage and in formulating commercialization strategies.

Acquisition of Intellectual Property Rights: Support to obtain major patents and other intellectual property rights.

Business Collaboration: We will promote collaboration with companies as needed to implement research in society.

Obtain Non-clinical PoC: We aim to obtain non-clinical PoC with a view to social implementation and progress to the subsequent clinical development phase.

About Us What is the Kashiwanoha Regenerative Medicine Platform?

This platform is being developed by the stakeholders (National Cancer Center, Teijin/J-TEC, Mitsui Fudosan) in the area surrounding Kashiwanoha Smart City (Kashiwa City, Chiba Prefecture), which aims to become a new hub for life sciences in Japan. Teijin and J-TEC, a Teijin group company that develops regenerative medicine products, have established CDMO base in Mitsui Link Lab Kashiwa-no-ha 1, which is operated by Mitsui Fudosan and is located next to the National Cancer Center Hospital East and the Exploratory Oncology Research & Clinical Trial Center. Each of them is working together to leverage their respective strengths and enhance synergies.

Member Support Groups

The National Cancer Center, a leader in cancer treatment and clinical research and development in Japan, the Teijin Group, which has a proven track record in the development of regenerative medicine products, and Mitsui Fudosan, which has played a role in the creation of Japan's life science community, have joined forces to provide support through industry-academia collaboration that enables analyses by experts in clinical and product development and the network support necessary for implementation.